Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Offered by National Institutes of Health; applications due June 2, 2027.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- Not specified by funder
- Deadline
- June 2, 2027
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision...
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
National Institutes of Health
Authority to Accept Unsolicited Proposals for Research Partnerships Notice of Intent (NOI)
Department of Housing and Urban Development
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
National Institutes of Health
NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)
National Institutes of Health